Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today it has nearly completed enrollment in its Phase II double-blind, placebo controlled, multi-dose, 10-Day Monotherapy study. The trial assessed the safety and effect of Monotherapy with SP01A, on viral load in HIV- positive individuals with evidence of increasing viral load, despite treatment with other antiretroviral therapy.
